CL2012002092A1 -
Pharmaceutical composition comprising vx-222 and vx-950; where vx-950 improves the pharmacokinetics of vx -222; use in the treatment of hepatitis c.
- Google Patents
Pharmaceutical composition comprising vx-222 and vx-950; where vx-950 improves the pharmacokinetics of vx -222; use in the treatment of hepatitis c.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex PharmafiledCriticalVertex Pharma
Publication of CL2012002092A1publicationCriticalpatent/CL2012002092A1/en
Método para mejorar los parámetros farmacocinéticos de VX-222 que comprende coadministrar VX-222 y VX-950; composición farmacéutica que comprende A) VX-222 de 20 Mg a 400 Mg y B) VX-950 de 100 Mg a 1500 Mg, útil para el tratamiento de un paciente infectado con HCV.Method for improving the pharmacokinetic parameters of VX-222 comprising co-administering VX-222 and VX-950; pharmaceutical composition comprising A) VX-222 of 20 Mg to 400 Mg and B) VX-950 of 100 Mg to 1500 Mg, useful for the treatment of a patient infected with HCV.
CL2012002092A2010-01-292012-07-27
Pharmaceutical composition comprising vx-222 and vx-950; where vx-950 improves the pharmacokinetics of vx -222; use in the treatment of hepatitis c.
CL2012002092A1
(en)
Compounds derived from 2'-substituted nucleosides, ns5a inhibitors; pharmaceutical composition that includes them; and its use in the treatment of hepatitis c.
Compounds derived from condensed nitrogen heterocycles, modulators of pi3k; pharmaceutical composition; and use in the treatment of a disease such as asthma, lupus, osteoarthritis, multiple sclerosis, cancer, among others.
Compounds derived from 2,7-naphthyridines-1-one, mediators of syk; pharmaceutical composition; and use in the treatment of inflammatory, respiratory, cellular proliferative or autoimmune disease.